profit from every $100 of sales.
$0$100
VivoSim Labs
$0.15+19.47% today
-93.3% in 1 year
1-year low $0.131-year high $2.92
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What VivoSim Labs sold, what it kept, and what it did with the cash.
Sales went from $1.50 million in 2022 to $144,000 in 2025, with -$2.49 million of profit last year.
SalesProfit
VivoSim Labs vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| VivoSim Labs | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads VivoSim Labs's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2 | 0 | 0 | 0 | |
| – | – | 0 | 0 | |
| -11 | -18 | -15 | -13 | |
| -11 | -17 | -14 | -2 | |
| -11 | -17 | -15 | -2 | |
| -15.84 | -23.76 | -19.25 | -1.70 | |
| – | – | 100.0% | 96.5% | |
| -765.3% | -4,792.2% | -13,840.4% | -8,761.1% | |
| -763.2% | -4,664.6% | -13,459.6% | -1,727.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 33 | 20 | 6 | 15 |
| Cash | 29 | 15 | 3 | 11 |
| Total debt | 2 | 2 | 1 | 1 |
| Total liabilities | 3 | 5 | 3 | 4 |
| 30 | 15 | 4 | 10 | |
| 1 | 1 | 1 | 1 | |
| -28.0% | -81.8% | -232.0% | -17.1% | |
| -37.9% | -112.6% | -407.4% | -23.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8 | -12 | -15 | -9 | |
| 0 | 0 | 0 | 0 | |
| -9 | -13 | -15 | -9 | |
| Dividends paid | – | – | – | – |
| 0 | – | – | – | |
| 2 | 2 | 2 | 1 |
Valuation
- –
- –
- –
- 0.5×
- 17.8×
- –
- –
- -369.5%
- -97.0%
- 0.0%
Profitability
- 96.5%
- -8,761.1%
- -1,727.8%
- -689.4%
- -228.3%
- -98.9%
- -15.6%
- -17.6%
- -255.4%
- 2,762.7%
Growth
- −54.2%
- –
- +35.5%
- –
- +26.3%
Financial health
- -4.7×
- 0.13
- 8.3%
- -881.1×
- 2.44
- 2.44
- 0.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 889
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 11, 2026 | -1.03 | -2.40 | +57.1% |
| Nov 6, 2025 | -0.98 | -2.28 | +57.0% |
| Aug 12, 2025 | -1.14 | – | – |
| May 30, 2025 | -3.48 | -2.28 | −52.6% |
| Nov 8, 2024 | -0.14 | -0.26 | +46.2% |
| Jun 30, 2024 | -2.74 | – | – |
| Mar 31, 2024 | -3.07 | – | – |
| Dec 31, 2023 | -4.74 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
70Pass
Philip Fisher
53No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
52No pass
Terry Smith
49No pass
Questions about VivoSim Labs
Is VivoSim Labs a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the VivoSim Labs AI analysis
What does VivoSim Labs do?
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. It is in Biotechnology.
Does VivoSim Labs pay a dividend?
No. VivoSim Labs does not pay a dividend at the moment.
Is VivoSim Labs stock halal?
No. VivoSim Labs does not pass our halal screen: its debt is 37% of its market value, at or above the 33% limit. How we check
How has VivoSim Labs stock done over the past year?
Down 93.3% over the past twelve months, to $0.15. It traded between $0.13 and $2.92 and is 94.7% below its high.
Who are VivoSim Labs's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with VivoSim Labs's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.